Keytruda: How PD-1 inhibition rewrote lung cancer care
Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor made by Merck. The US FDA approved it in 2014 as the first PD-1 drug of its kind. The real shift came in 2016, when a trial limited to patients whose tumors expressed PD-L1 at 50 percent or higher showed the drug more than doubled progression-free survival over chemotherapy. By screening for the patients most likely to respond, it became the leading immunotherapy for lung cancer.
Most cancer drugs have a quiet backstory behind the headlines. Keytruda is now one of the most prescribed cancer medicines on the planet, but plenty of people only know it as the K drug, or as the therapy a famous patient once credited. The interesting part is not the fame. It is how a company that started a step behind its rival turned one smart trial design into one of the biggest wins oncology has seen in years.
This piece covers what Keytruda is, how it works, why a single trial changed its path, and what readers should actually understand about the benefits and the risks.
What Keytruda is and what it treats
Keytruda is the brand name for pembrolizumab. It is a humanized IgG4 monoclonal antibody, meaning a lab-built protein engineered to grab a specific target in the body. That target is PD-1, short for programmed cell death protein 1.
PD-1 belongs to a class of medicines called immune checkpoint inhibitors. These do not attack the tumor directly. They take the brakes off the patient’s own immune system so it can find and attack cancer cells.
The US FDA approved Keytruda on September 4, 2014, which made it the first PD-1 inhibitor approved in the United States. Europe followed in the middle of 2015, and China approved it in July 2018 as the second PD-1 inhibitor available there. By the third quarter of 2021, regulators in 93 countries and regions had approved it across 31 indications covering 16 types of cancer, with extra approvals for tumors defined by biomarkers such as MSI-H and TMB-H.
How Keytruda works in the body
Picture the immune system as a defense force and T cells as its front-line soldiers. T cells carry a protein on their surface called PD-1. Healthy tissue uses a partner protein, PD-L1, as a kind of handshake that tells the T cell to stand down. That handshake keeps the immune response from damaging normal tissue.
Tumors exploit it. Many cancers display PD-L1 on their surface and use it to convince T cells they are harmless. The soldier gets the signal, assumes the tumor is friendly, and moves on.
Keytruda binds to PD-1 on the T cell. Once it occupies that spot, PD-L1 and its relative PD-L2 can no longer dock. The stand-down message never arrives. The T cell stays switched on and goes back to attacking the tumor.
This sounds a lot like other PD-1 drugs, and the core idea is the same. The differences sit in the fine print: the exact patch of PD-1 that Keytruda grabs, and an engineered change in the antibody’s tail known as the IgG4 S228P mutation. Those details shape how the drug behaves and how patients tolerate it, which matters when we line it up against its main competitor.
The trial that changed everything: KEYNOTE-024
When the first PD-1 drugs reached the market, they landed almost together. A rival drug from another company reached Japan first in July 2014, while Keytruda reached the United States two months later. For a while the two looked like near twins.
Then Merck made a call that looked narrow at the time and turned out to be the whole game.
The scientists behind Keytruda knew something practical: PD-1 inhibitors do not help everyone. Patients whose tumors express high levels of PD-L1 tend to respond far better. So instead of testing the drug in all comers, they built a first-line lung trial called KEYNOTE-024 that enrolled only patients whose tumors showed PD-L1 at 50 percent or higher.
That filter is stricter than it sounds. Only about 30 percent of advanced non-small cell lung cancer patients without an EGFR or ALK mutation land in that high-expression group. By focusing there, the trial stacked the deck toward patients most likely to benefit.
The results, presented in 2016, stopped the room.
| Measure | Keytruda | Chemotherapy | Note |
| Median progression-free survival | 10.3 months | 6.0 months | Risk of progression reduced, P below 0.001 |
| 6-month overall survival rate | 80.2 percent | 72.4 percent | P equals 0.005 |
| Objective response rate | 44.8 percent | 27.8 percent | More tumors shrank |
| Grade 3 or higher adverse events | 26.6 percent | 53.3 percent | Fewer severe side effects |
Every efficacy and tolerability endpoint favored Keytruda. Median progression-free survival moved from 6 months to just over 10. On the strength of that result, the FDA approved Keytruda for first-line use in PD-L1 high advanced non-small cell lung cancer in October 2016.
Why the rival stumbled at the same moment
The most useful part of this story is what happened to the competing drug almost at the same time. That drug’s first-line lung trial, CheckMate-026, used a wider enrollment threshold. It included patients with PD-L1 at 5 percent or higher.
The result was a surprise miss.
| Measure | Competing PD-1 drug | Chemotherapy | Note |
| Median progression-free survival | 4.2 months | 5.9 months | No advantage shown, P equals 0.25 |
| Objective response rate | 26 percent | 33.5 percent | Not significant |
| Median overall survival | 14.4 months | 13.2 months | Not significant |
On paper the two drugs share the same mechanism. The difference was not the molecule. It was the trial design. By setting the PD-L1 cutoff at 5 percent, the rival study pulled in many patients whose tumors were unlikely to respond, which washed out the treatment signal and hid the benefit. Keytruda’s stricter 50 percent cutoff kept the signal clean.
The lesson travels outside oncology. The same medicine can read as a failure or a triumph depending on who you give it to. Choosing the right patients beat casting a wide net.
Expanding the win: KEYNOTE-042, 189, and 407
Merck did not stop at one trial. A run of studies pushed Keytruda from a narrow high-expression group to most patients with advanced non-small cell lung cancer.
KEYNOTE-042 lowered the bar for single-drug use, extending the benefit from PD-L1 at 50 percent down to 1 percent. KEYNOTE-189 paired Keytruda with pemetrexed and platinum chemotherapy against non-squamous disease, reaching a 12-month survival rate of 69 percent versus 49 percent for chemotherapy alone, a 51 percent cut in the risk of death. KEYNOTE-407 added it to carboplatin and paclitaxel for squamous disease, lifting median overall survival from 11.3 months to 15.9 months.
Together these studies moved Keytruda from a targeted option for a select few to the front-line standard across both main subtypes of advanced non-small cell lung cancer.
Why it ended up with the most approved uses
Beyond lung cancer, Keytruda gathered indications faster than almost any medicine on the shelf. By late 2021 it held 31 approved uses across 16 cancer types worldwide, plus approvals tied to tumor biomarkers rather than organ site. In China it was the PD-1 inhibitor with the most approved indications at the time, and by 2023 it had filed for a twelfth local indication.
That breadth comes from the biology. Because the drug frees the immune system instead of chasing one mutation, it can work across many tumor types, especially when a tumor uses PD-L1 to hide. The biomarker-based approvals, such as for MSI-H and TMB-H tumors, let one drug treat cancers in different organs that share the same molecular fingerprint.
The Nobel connection
The science behind Keytruda earned its discoverers the top prize in medicine. The PD-1 protein was identified in 1992 by Tasuku Honjo, while James Allison mapped the related CTLA-4 checkpoint. In 2018 the two shared the Nobel Prize in Physiology or Medicine for showing how to release the immune system’s brakes on cancer.
From the basic discovery to the first PD-1 drug reaching patients took more than two decades. From that approval to the Nobel took four years. The arc shows how slow, patient foundational research eventually turns into treatments that touch millions of lives.
Who can use Keytruda and who should be careful
Keytruda is a prescription medicine used for specific approved indications, decided by an oncology specialist. In practice it is used across melanoma, non-small cell lung cancer in several combinations, esophageal and gastroesophageal cancers, head and neck squamous cell carcinoma, certain colorectal cancers defined by MSI-H or dMMR status, and triple-negative breast cancer in high-risk early settings, among others.
A PD-L1 test is usually required before single-drug use. The threshold differs by cancer type, and a specialist has to interpret the result.
Some groups should avoid the drug or use it only with caution. People with a known allergy to pembrolizumab or its components should not take it. It is not recommended during pregnancy or breastfeeding, and people who can become pregnant must use strict contraception during treatment and for at least four months after the last dose. Active autoimmune disease, organ transplant, and a history of interstitial lung disease all call for careful specialist assessment.
The safety picture: immune-related side effects
Because Keytruda revs up the immune system, it can cause immune-related adverse events, sometimes serious or fatal. These can show up during treatment or months after stopping.
| System | Possible reaction | Signs |
| Lungs | Immune-related pneumonitis | Cough, chest pain, breathlessness |
| Intestine | Immune-related colitis | Diarrhea, belly pain, blood in stool |
| Liver | Immune-related hepatitis | Raised liver enzymes, yellowing skin |
| Endocrine | Thyroid, pituitary, type 1 diabetes, adrenal issues | Thyroid changes, high blood sugar, fatigue |
| Kidneys | Immune-related nephritis | Rising creatinine, less urine |
| Skin | Severe rash, rare severe skin reactions | Rash, mouth or eye lining damage |
| Nerves | Immune-related neuropathy | Rare but serious |
The response scales with severity. A grade 2 event usually means pausing the drug and giving corticosteroids. A grade 3 or 4 event means stopping it for good and using higher-dose steroids, with other immune-suppressing medicines added for severe cases such as heart muscle inflammation.
In practical terms, Keytruda is given by intravenous infusion over about 30 minutes, typically every three weeks at a fixed 200 mg dose. Any new or worsening symptom, a persistent cough, diarrhea, yellowing of the skin, extreme fatigue, or a racing heart, should send a patient to the doctor without delay.
One more thing worth knowing: in some markets the drug sits outside public insurance coverage, which can mean a heavy out-of-pocket cost. Patients should plan for that before starting.
Lessons worth keeping
A few ideas from this story travel well past medicine.
Precision beats breadth. Keytruda’s edge in first-line lung cancer came less from a superior molecule and more from matching the drug to the patients most likely to respond through a biomarker test. Finding the right people is often the highest form of problem solving.
Failure and success sit close together. The rival trial did not fail because the drug was weak. It failed because the enrollment rules let in the wrong patients. In science and in business, how you design the test can matter as much as what you are testing.
Foundational research pays off slowly. The gap between discovering PD-1 and winning a Nobel was 26 years. That slow, freely pursued inquiry is what made the second revolution in cancer treatment possible.
Rivalry can serve patients. The race between the two PD-1 drugs was not a zero-sum game. Their competition pushed immunotherapy from a concept into a standard of care, giving patients options that did not exist a decade earlier.
Bottom line
Keytruda turned a simple insight into a clinical and commercial triumph: match the drug to the patients most likely to respond, then expand carefully from there. Its story is a clear example of how trial design, not just chemistry, decides what a medicine can achieve. For readers the practical takeaway is this. Biomarker testing and specialist guidance are the gatekeepers to these benefits, and the strong upside comes with real, sometimes severe risks that demand close monitoring.
This article explains how a cancer medicine was developed and studied. It is not medical advice. Pembrolizumab is a prescription oncology drug that must be used under the supervision of a qualified specialist, with decisions based on approved indications and biomarker testing such as PD-L1, MSI-H or dMMR, and TMB. Treatment choices should always follow your own physician’s guidance.
Frequently asked questions
What is the difference between Keytruda and Opdivo?
Both are PD-1 checkpoint inhibitors with the same broad mechanism of freeing T cells to attack tumors. The practical differences show up in the details of the antibody, the engineered tail region, and the side-effect profiles seen in clinical use. They are not interchangeable in every setting, and trial designs rather than the molecules themselves explained why one outperformed the other in first-line lung cancer.
How does pembrolizumab work against cancer?
It binds the PD-1 protein on T cells and blocks the PD-L1 and PD-L2 signals that tell those cells to stand down. With the brake released, the patient’s own T cells can recognize and attack tumor cells that were previously hiding.
Why did Keytruda succeed in lung cancer when a rival PD-1 drug did not?
The deciding factor was patient selection. Keytruda’s KEYNOTE-024 trial enrolled only patients with PD-L1 at 50 percent or higher, concentrating those most likely to respond. The rival CheckMate-026 trial used a lower 5 percent cutoff, which diluted the treatment signal and missed its primary goal.
What were the KEYNOTE-024 results?
In 305 patients with PD-L1 at 50 percent or higher, median progression-free survival was 10.3 months with Keytruda versus 6.0 months with chemotherapy. The 6-month survival rate was 80.2 percent versus 72.4 percent, the response rate was 44.8 percent versus 27.8 percent, and severe side effects were less common.
Is PD-L1 testing required before Keytruda?
For single-drug use, yes, a PD-L1 test is usually needed to confirm expression level, and the threshold varies by cancer type. A specialist must interpret the result, because the right cutoff depends on the specific indication.
What are the most serious side effects?
The drug can cause immune-related reactions affecting the lungs, intestines, liver, endocrine system, kidneys, skin, and nerves. These can be severe or fatal and may appear during treatment or after it ends. Grade 3 or 4 events generally require permanently stopping the drug and using high-dose steroids.
How is Keytruda given?
It is delivered by intravenous infusion over about 30 minutes, most often every three weeks at a fixed 200 mg dose, under the care of an oncology team that monitors for side effects.
How many cancers is Keytruda approved for?
By late 2021 it had 31 approved indications across 16 cancer types worldwide, plus biomarker-defined uses such as MSI-H and TMB-H tumors, making it one of the most broadly approved cancer medicines in use.
Why did the 2018 Nobel Prize matter to this drug?
The prize honored the discovery of immune checkpoints, including PD-1 by Tasuku Honjo and CTLA-4 by James Allison. Keytruda is built directly on the PD-1 discovery, so the award recognized the science that made the drug possible.
Is Keytruda covered by insurance?
Coverage varies by country and plan. In some markets the drug is not on public insurance, which can mean substantial out-of-pocket cost. Patients should confirm coverage and plan financially before starting treatment.
